SIGNS OF COGNITIVE DYSFUNCTION IN PATIENTS WITH MULTIPLE SCLEROSIS IN CONDITIONS OF COVID-19

Abstract

At the stage of new infections that are conquering the whole world, in particular with the COVID-19 pandemic worldwide, first identified at the end of 2019 in the People's Republic of China (PRC), in the city of Wuhan (Hubei province), it has been proven that it affects not only the brain and spinal cord, but also other organs, and the system, in connection with which an in-depth study is still underway, the development of new diagnostic tools, treatment and prevention of its complications. The aim of the study was to study cognitive functions in patients with multiple sclerosis in conditions of COVID-19 (infected with SARS-CoV-2). 42 patients with multiple sclerosis were studied, of whom 24 (57.1%) suffered COVID-19 of varying severity (group 1, comparative), and 18 (42.9%) remained intact (group 2, main). All patients underwent PCR analysis confirming infection with SARS-CoV-2, a study of C-reactive protein (CRP), ESR, white blood cell count, D-demir, urea and creatinine in venous blood. Cognitive impairment (CN) developed not only in patients with multiple sclerosis infected with coronavirus infection, but also in similar patients without COVID-19 infection. More extensive neuropsychological testing and analysis of the relationship between inflammatory markers (ESR, blood leukocytes, CRP) and CN were performed. The analyses were compared retrospectively and prospectively, 10-12 days after infection, at the stage of recovery. The presence of coronavirus pathology in patients with multiple sclerosis led to an aggravation of the clinical picture of the disease, mutually burdening each other, with a significant impact on the quality of life, the development of disability, through motor, somatosensory, visual, cognitive and neuropsychic disorders